PT Kimia Farma Tbk (ISX:KAEF) Total Receivables: Rp1,242,511 Mil (As of Mar. 2026)


ISX:KAEF PT Kimia Farma Tbk ISX:KAEF
51 GF Score
Price Rp454.00
GF Value Rp581.54
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is PT Kimia Farma Tbk Total Receivables?

PT Kimia Farma Tbk ISX:KAEF +0.89% 51 Total Receivables is Rp1,242,511 Mil as of Mar. 2026. GuruFocus rates ISX:KAEF with a GF Score™ of 51/100 and a GF Value™ of Rp581.54 (Modestly Undervalued). The stock has 4 warning signs investors should review.

PT Kimia Farma Tbk's Total Receivables for the quarter that ended in Mar. 2026 was Rp1,242,511 Mil.

PT Kimia Farma Tbk Total Receivables Related Terms

PT Kimia Farma Tbk Total Receivables Historical Data

* Premium members only.

The historical data trend for PT Kimia Farma Tbk's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PT Kimia Farma Tbk Total Receivables Chart

PT Kimia Farma Tbk Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,191,611.98 2,349,407.54 1,872,770.01 1,352,384.94 1,205,802.91

PT Kimia Farma Tbk Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,571,670.88 1,684,830.41 1,582,482.24 1,205,802.91 1,242,510.60
ISX:KAEF
51GF Score
PT Kimia Farma Tbk ISX:KAEF
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PT Kimia Farma Tbk Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of Rp1,242,511 Mil mean?
PT Kimia Farma Tbk (ISX:KAEF) has a Total Receivables of Rp1,242,511 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on PT Kimia Farma Tbk and its competitors.
Is PT Kimia Farma Tbk's Total Receivables too high?
PT Kimia Farma Tbk's current Total Receivables is Rp1,242,511 Mil. Overall, PT Kimia Farma Tbk has a GF Score™ of 51/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Kimia Farma Tbk's Total Receivables compare to MCK and CAH?
PT Kimia Farma Tbk's Total Receivables of Rp1,242,511 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Medical Distribution company?
A good Total Receivables depends on the Medical Distribution industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on PT Kimia Farma Tbk and its competitors. PT Kimia Farma Tbk's current Total Receivables is Rp1,242,511 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Kimia Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Kimia Farma Tbk (ISX:KAEF) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp581.54, compared to a current price of Rp454.00 — trading 21.9% below its estimated fair value. The current Total Receivables is Rp1,242,511 Mil. PT Kimia Farma Tbk's overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For PT Kimia Farma Tbk (ISX:KAEF), the current Total Receivables is Rp1,242,511 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PT Kimia Farma Tbk (ISX:KAEF) Overvalued in 2026?

Based on GuruFocus' analysis, PT Kimia Farma Tbk stock appears to be undervalued. The current stock price of Rp454.00 is trading 21.9% below its estimated GF Value™ of Rp581.54. GuruFocus considers PT Kimia Farma Tbk to be Modestly Undervalued.

Key valuation signals for ISX:KAEF:

  • Total Receivables: Rp1,242,511 Mil
  • GF Value™: Rp581.54 vs. price of Rp454.00 (21.9% below fair value)
  • GF Score™: 51/100 with 4 warning signs

No single metric tells the full story. See the ISX:KAEF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PT Kimia Farma Tbk Business Description

Address Jalan Veteran No. 9 Gambir, Jakarta Pusat, Jakarta, IDN, 10110
PT Kimia Farma Tbk is an Indonesia-based company engaged in the production and distribution of healthcare products. It operates through the following segments: Manufacture, Distribution, Retail, and Others. The company provides its products in categories including OTC & Herb, Ethical, Cosmetic, Generic, and others. Some of its product offerings include Alergine, Kimoxil, Loprezol, Enkasari, and Batugin among others. It generates maximum revenue from the Retail segment.
51GF Score

Get the complete analysis for ISX:KAEF

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Rp454.00
Price
Rp581.54
GF Value